Search results

Ilonov develops first-in-class biotherapies unlocking the muscle secretome to counter metabolic dysfunction. Our lead assets, based on human-centric discovery, preserve mitochondrial health, maintain tissue function and reduce chronic inflammation, addressing the unmet need in diabetes and MASH.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

We are a small CRO providing highly tailored services to customers with clinical trials and regulatory consulting needs. With expertise in drug, food supplements, medical devices, diagnostics and software, we support you at every stage of product's lifecycle, from preclinical development to market.

Asemblis is a Swiss TechBio company developing scalable, human-relevant in vitro models for obesity and metabolic disorders. The company partners with industry and research organizations to support translational R&D and decision-making in drug development

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

RC TRITEC is an established company offering custom synthesis of tritium-labeled compounds, a range of tritiated catalog products, storage service and disposal of radiochemicals. We have over 60 years of experience in the safe handling of tritium gas using in-house developed high-vacuum equipment.

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Topadur Pharma AG, founded in 2015 in Schlieren, is a clinical-stage biopharmaceutical company. Leveraging its proprietary DualTOP™ platform, Topadur develops dual-acting molecules that restore cGMP levels, repairing microcirculation, promoting tissue regeneration, and addressing oxygen deficiency.

Swiss Consultant-Network GmbH is developing a new data management system that can be used as a framework for the integration of heterogeneous data in the field of biological research and development. We offer our customers IT engineers, who have in-depth knowledge of computer science disciplines.

Jantar is a clinical R&D company in the field of chronic rhinosinusitis. Its product is a nasal spray of dicholine succinate. Clinical efficacy has been demonstrated by well-documented case studies which showed that the drug relieves all symptoms of the disease. A PCT patent has been filed.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

As a health company, we envision empowering global well-being by pioneering biological solutions drawn from nature. Our mission: Unlock the full potential of exDNA across diverse indications. Our AND Technology Platform has the primary focus on controlling disease caused by pathogenic bacteria.

CMC & More delivers hands-on CMC, regulatory, and quality expertise for biotech and pharma. We bridge discovery to first-in-human trials and beyond with GMP-compliant CMC strategies that derisk development and transform complex products into approval-ready assets.

At Lederer & Partner AG, we transform complex visions into clear successful results. Our expertise in engineering, construction, commissioning, qualification, and operation, we develop project models that are precisely aligned with your goals. As your trusted partner, we deliver lean, efficient solutions.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

EVIIVE develops single extracellular vesicle-based diagnostics to predict immunotherapy response and monitor tumor microenvironment in real time. Our platform integrates advanced flow analytics and machine learning for precision oncology applications.

TheraPPI Bioscience, a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases and inflammation

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

SPILLO supports pharmaceutical and biotech R&D teams through unbiased, in silico, proteome-wide identification of targets and off-targets. Using exclusive, experimentally validated, physics-based computational technology, SPILLO reduces scientific risk and clarifies mechanisms in drug development.

Devintec Pharma is focused on B2B partnerships through out-licensing innovative substance-based medical devices. We apply DevinPro™ technology, that addresses root causes and creates a protective barrier for lasting relief, to our patended products in gastroenterology, dermatology, and gynecology.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

Nxera Pharma is a tech-driven biopharma company focused on specialty medicines for unmet needs in Japan and globally. With 30+ active programs in neurology, GI, immunology, metabolic, and rare diseases, Nxera employs 350+ people across Japan, the UK, Switzerland, and South Korea.

TransHeps specializes in iDILI causality assessments, supporting drug developers in clinical trials and managing drug-induced liver injuries. Leveraging cutting-edge expertise, we provide reliable solutions to improve drug safety and accelerate pharmaceutical innovations.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

Philip Morris International (PMI) is a leading international tobacco company with the objective to replace cigarettes with smoke-free products. The goal is to offer adult smokers, who would otherwise continue to smoke, better alternatives that are scientifically substantiated.

Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

We "think data" and "speak biology", partnering with our clients to transform lives. Our team combines deep biological knowledge with proven expertise in AI & bioinformatics to tackle complex data challenges. Via our AI-native Bio|Verse platform, we accelerate biomarker discovery & drug development.

At CxO, we drive biotech startups toward growth by optimizing resource management and operational efficiency. As partners, we empower firms to innovate and scale. Our veteran team offers strategic insights to accelerate timelines, optimize ROI, and enhance workflows, ensuring client success

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Precise Health develops AI-powered platforms for bacteriophage discovery, host-matching, and engineering. We serve hospitals, biotech, and pharma in the $50B+ anti-infectives and diagnostics markets, addressing the urgent global threat of antimicrobial resistance

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

We provide a portfolio of models for efficacy pharmacology in autoimmunity, immuno-oncology, and transplantation. Our humanized mouse and tumor xenograft platforms enable translational evaluation of biologics, cell therapies, and innovative immunotherapies.

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Complyomics supports Life Sciences companies in core areas as: Build and maintain robust Quality Systems in compliance with regulatory requirements. Provide externalized QA. Audits Develop expertise in Bioanalytical / Analytical areas Identify / assess / supervise sub-contractors Due diligence

Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.

NanThermix SA is a pioneer in nanoscale temperature control within living cells for applications across life sciences, from academic research to biomedical fields, based on a novel technollogy of all-optical nanodiamond heater / thermometer.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.

At ATANIS Biotech AG, our mission is to revolutionize the way allergies are diagnosed and thereby to improve treatment success Our novel cell-based assay allows us to quantify patients allergic status with unparalleled diagnostic accuracy, without needing to expose patients to the culprit allergen.

Oryl Photonics has developed a groundbreaking laboratory instrument for solubility and aggregation measurement. It is the world's first accurate and rapid solubility testing solution that saves precious drug compounds.

iCure offers the Cardinal platform for developing digital health applications that comply with cybersecurity standards, with end-to-end encryption, FHIR interoperability, and open-source SDKs, accelerating innovation in e-health. iCure is ISO27001,ISO13485,HDS certified and GDPR and NIS2 compliant.

Altorfer Engineering is a specialized contractor and consulting company. We provide expertise in engineering and project management services, and technology transfers. Our focus is on developing and managing aseptic formulation and fill-finish processes tailored to your receiving sites.

inSEIT solves the challenges of enzyme immobilization and unlocks the potential of immobilized biocatalysts for the production of APIs and chemical intermediates. We use bioinformatic tools to reduce the risk, time and cost associated with biocatalyst development.

We at INCAPTEK are developing advanced drug delivery systems. We deliver drugs at the right place, in the right dosage, and at the right time. Our smart, programmed-shell micro(nano)capsules can be used for controlled and targeted drug delivery for both biotech and medtech.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof of concept, and enhancing early stage decision-making.Expertise tailored to your needs, from small biotech to pharma.

Our goal is to deliver innovations in health care through cutting-edge tech and research, addressing challenges in antimicrobial therapies to improve patient outcomes. We are committed to delivering superior treatments that promote healing and improve quality of life globally.

I work WITH my clients as a freelance science business development project manager. Having said that, Boehler Life Science Advice is not typical consultancy, even though strategic planning and execution is an important part of supporting my clients.

We are a clinical research team delivering patient-centric clinical investigations across Europe and MENA. We combine strong site access with DCT/hybrid delivery, an integrated digital trial stack (eTMF, eCRF, eCOA, RTSM), and risk-based monitoring to start fast, run clean, and stay audit-ready.

VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM- Pharma, which focus on special methods of personalized medicine

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricate novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).

On demand Outsourcing & Supply Chain Experts and Solutions for Innovative Biotechs & Medtechs. Kisco gives access to teams of seasoned experts to support your development cycle, from Preclinical to Clinical Research (CRO), Supply Chain set up, outsourced Manufacturing (CDMO), and R&D Operations.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Cetacea Clinical offers Clinical Operations Services and functional services, including trial management, regulatory compliance, data management, and quality oversight. Our robust Quality Management System ensures efficient, high-quality clinical trials from start to finish.

Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a

NexMR offers the first technological solutions to do drug discovery on a benchtop NMR spectrometer without compromising speed and data quality.

AlphaMol is an AI-based bio-pharmaceutical company focusing on G protein-coupled receptor drug discovery. The Cofounders of AlphaMol are leading scientists in the area of GPCRs. Many essential molecular mechanisms and biotechnology were invented by the members of AlphaMol.

Pheida develops and deploys biotech solutions at scale to reduce GHG emissions and other pollutants, and to remediate contaminated soil and water. Pheida products combine advanced biotech, proprietary application engineering to deliver unique and commercially attractive solutions.

Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.

Whatever your level of maturity regarding the valorization of data in your company, our Luciders are your trusted advisors to design and implement a data roadmap. We will work closely with your different business units to explore how data, advanced analytics, AI and ML can solve complex challenges.

Solid Drug Development (SDD) is a Strategic and Operational consultancy based in Geneva. The company founded in 2010 is specialized in the development of Biotech and Pharma products.

We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment..

4bases is a company active in the fields of prevention and precision medicine. 4bases is a certified company working accordingly to the IVDR regulation. Our products are reagent kits for platform-independent New Generation DNA Sequencing (NGS), data analysis software and diagnostic protocols.

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 to treat rare diseases, cancer, and neurodegenerative diseases, and uniquely addresses unmet medical needs.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Streefkerk Life Science Consultancy (SLSC) supports small pharmaceutical companies to improve efficiency, comply with regulations and standards, and excel in designing high-quality clinical development plans, to deliver new drugs to patients as soon as safely possible.

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers - Cancers - Ovarian, Peritoneal

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

MD Bioproducts, with over 30 years of experience, is a worldwide manufacturer and supplier of high-quality antibodies, reagents, peptides, assays, and disease-induction reagents supporting research in arthritis, autoimmune diseases, immunology, inflammation, neurology, metabolism, and oncology.

Immune response on a chip!

therainnova AG provides strategic and operational regulatory affairs consulting for the biopharmaceutical industry in Europe. With expert leadership and a strong partner network, we offer end-to-end regulatory support, including due diligence, to maximize portfolio value.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies. We leverage our world-class protein engineering & conjugation platform to generate novel protein therapeutics for cancer and other indications. Bright Peak is located in Basel and San Diego.

Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.

At Alithea Genomics we develop, produce and commercialize cutting-edge solutions for drug and biomarker discovery based on gene expression. Our products provide high throughput and cost-efficiency, which is ideal for large-scale projects such as drug screening and biomarker discovery.

Vaderis Therapeutics AG is a clinical stage biotech focussing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020.

Novochizol SA researches and develops applications of Novochizol, a unique chitosan nanoparticle technology that yields different carriers of small molecules, peptides, nucleic acids and proteins for sustained, localized delivery to any living tissue, with intracellular targeting potential.

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

MUVON is a Swiss, clinical stage biotech company with the goal of revolutionizing the treatment of diseases caused by muscle damage or degradation through the use of the patients' own cells. Our initial area of focus is the treatment of stress urinary incontinence in women (PhII completed)

Centenara is an integrated biotechnology platform company that develops and improves therapies and technologies to promote healthy aging and prolong lifespan. We provide start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit our aging population.

Ceidos is a Swiss biotech company developing the C-Netics, an innovative device for automated cell culture monitoring. Their mission is to optimize bioproduction processes for modern treatments through automation and innovative technologies.

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications. We are rapidly advancing our pipeline of antibodies and antibody-drug conjugates through clinical development.

DiNAQOR has developed a proprietary technology platform and manufacturing capabilities designed to overcome the challenges and limitations of early-stage gene therapy development.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders through the modulation of a new drug target in the endocannabinoid system enabling restoration of the natural functioning of the brain

Sferalp is specialized in the formulation of Self Emulsifying Oils (SEFO) containing extracts or API. SEFO maximize gastro-intestinal absorption. We have developed a SEFO based on natural food components (Patent pending). We provide development in the field of electro- and conventional spray drying.

Cerdia, headquartered in Basel, is a pioneer in cellulose acetate tow since 1912 and a global quality and innovation leader of filter tow for cigarette manufacture. We are developing innovative applications and processes that will define Cellulose Acetate as a sustainable raw material in the future.

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

Artidis® is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. Artidis focuses its efforts on solid tumors to enhance responses to chemo, immuno, and cell therapies, driving precision in cancer care.

abc biopply AG is pioneering NAM technologies and organoid CRO services that boost in vitro studies for drug discovery and development to IND relevance using its proprietary 3D CoSeedis Multi-Organoid in chip Technology™ on clinically relevant disease models (oncology, neurology, obesity and others)

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

Medistri is a Swiss service provider supporting medical device and pharmaceutical manufacturers from pre-clinical development to industrialization, with integrated sterilization, laboratory, packaging validation, and manufacturing services, ensuring compliance and product safety.

Ectica Technologies supplies hydrogel-based tools to the biopharmaceutical and life science industries for drug discovery and bioresearch applications. Ectica Technologies manufactures and supplies the 3DProSeed product line for drug discovery and research in oncology, immuno-oncology and neurosciences. It en

Wyss Zurich is a joint accelerator of ETH & University of Zurich. Our mission is to drive the clinical translation of outstanding scientific discoveries into new therapies for patients and innovations in the fields of regenerative medicine and robotics, and hybrid technologies in these fields.

Synple Chem was founded to develop new easy to use automated laboratory equipment for chemistry research labs.

Tepthera is a spin off from the ETH Zurich focusing on product development in the field of cancer immunotherapy, autoimmune- and infectious diseases.

QuartzBio SA is a Swiss data driven biomarker discovery and validation company and the trusted partner of companies and institutions for their in-silico biomarker discovery programmes. Leveraging a unique Biomarker Optimisation Software System – BOSS™ – we discover and validate biomarkers.

SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 750 institutions in over 70 countries.  Our network advances data-driven medicine to improve health outcomes and economics worldwide.

SpacePharma provides researcher, institutes and commercial companies an easy and affordable access to the microgravity environment. Our novel technology enables researchers to perform complex chemical and biological experiments with our proven cutting-edge remote-control technology and labs in space.

SAKK is a non-profit organization since 1965 investigating the efficacy and tolerability of new cancer therapies and further develops existing tumor treatments in adults. Our objective is to apply the best possible treatment. We see ourselves as the Swiss competency center for oncology trials.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.

SGS M-Scan is a world leading GLP/cGMP contract analytical services group dedicated to providing high quality analysis of biopharmaceuticals. Studies involve molecules at all stages of product development.

Regen Lab is a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma from the patient’s own blood, used either alone or combination with hyaluronic acid or other fresh autologous cells from the patient’s fat or bone marrow.

PeptART manufactures a large variety of amino acid derivatives, pseudoprolines, and peptides on-site in our facility in Switzerland. We deliver our products from a few grams up to several tens of kg worldwide. Trust builds on quality and expertise – PeptART – Your Swiss pARTner in Peptide Chemistry.

Oculis is a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Headquartered in Switzerland, Oculis is led by an experienced management team and supported by leading international healthcare investors.

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Novassay is a biotech active in the area of Ion Channel therapeutics with focus in neuropathic pain and Oncology. We have a portfolio of assets currently in development (approaching IND stage) and interested in partnering and R&D collaborations.

Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018. We now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

Memo Therapeutics AG develops therapeutic antibodies for viral infections and cancer. Lead asset potravitug targets BKV in kidney transplant recipients; Phase II SAFE KIDNEY data, presented in Nov 2025, support a planned Phase III start in 2026. MTx is also building an oncology discovery pipeline.

MetrioPharm AG, a clinical stage biopharmaceutical development company based in Zurich with a subsidiary in Berlin, Germany, has developed a platform of small molecule drug candidates (oral and i.v.) which targets the modulation of immune cell metabolism without suppressing the immune system.

Microsphere (MS) is a CDMO focused on new developments, cGMP manufacturing, R&D, analytical and regulatory support. MS is able to address complex challenges, including formulations for poorly water-soluble drugs, considering the extensive expertise in Spray Drying and Capsule Filling.

Lunaphore has developed an innovative device for cancer tissue diagnostics. Its award-winning technology based on microfluidics aims to achieve faster & more precise results than current techniques. It was founded in 2004 with the vision of bringing –omics like approaches to tissue diagnostics. Lunaphor

Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile populations, e.g. children, cancer patients and the elderly, who may be already on multiple medications.

Life Technologies Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community.

Laves-Arzneimittel GmbH has focused on the exploration and development of preparations based on the probiotic Escherichia coli strain Laves discovered in 1931 by Dr. Wolfgang Laves.

Kinematica is a mechanical engineering company from Lucerne. We have our expertise in the field of homogenization and dispersion equipment form lab to production scale. We focus on close collaboration with our customer to built and scale equipment on request - for homogenization perfected.

Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Clinical trials for the treatment of breast cancer as well as Parkinson's disease are conducted in Swiss hospitals.

InterAx developed a unique drug discovery platform integrating biochemistry, cellular pathways mathematical modelling and AI to decode the cellular communication language. This novel approach enables the rapid and precise identification of differentiated effective and safe candidates.

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing novel human immunomodulatory proteins for cancer with a specific role in innate immunity.

Calliditas is a commercial stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, specializing company in NOX therapies, French & Swiss based.

Our R&D center for biologics in Switzerland has end-to-end capabilities to discover Novel Biological Entities (NBEs) and develop them from inception through to pre-clinical & clinical studies. It is also fully equipped to manufacture clinical trial-size batch materials.

Genedata transforms biopharma data into intelligence by combining deep science, technology, and AI domain knowledge. From early discovery to the clinic, the Genedata Biopharma Platform digitalizes and automates complex data workflows, driving innovation and data-based decisions to maximize ROI.